Schistosoma Species (Blood Fluke) Test · Stool

If you have ever swum, waded, or bathed in freshwater in sub-Saharan Africa, parts of South America, the Middle East, or Southeast Asia, a parasitic worm may have entered your body through your skin and set up residence in the blood vessels around your bladder or intestines. Many people carry these worms for years or decades without obvious symptoms, while quiet inflammation builds in the organs the worms call home.

This stool-based test looks for the eggs of Schistosoma (the scientific name for blood flukes) that adult worms have released into your gut. A positive result means active infection that should be treated. A negative result from a single sample does not fully rule infection out, which is why this test is often paired with blood-based antibody or antigen testing.

Why This Matters

Schistosomiasis is caused by blood flukes of the genus Schistosoma and affects hundreds of millions of people worldwide. The infection begins when larvae shed by freshwater snails burrow through your skin, mature into adult worms, and lodge in the veins of your bladder or intestines. There, paired adults produce eggs for years, and it is those eggs, lodged in tissue, that drive the disease.

Different species cause different patterns of disease. S. mansoni, S. japonicum, S. mekongi, and S. intercalatum cause intestinal schistosomiasis, while S. haematobium causes urogenital disease affecting the bladder and kidneys. In Africa, S. mansoni and S. haematobium dominate. In East and Southeast Asia, S. japonicum and S. mekongi are the main human species. Because S. haematobium eggs are typically shed in urine rather than stool, this stool-based test is best at detecting the intestinal species, and a urine test or serology may be needed to pick up urinary schistosomiasis.

Liver and Gut Disease

When S. mansoni or S. japonicum eggs get trapped in the liver, they trigger inflammation and scarring that can progress over years to portal hypertension, enlarged spleen, and advanced fibrosis. A population-based cohort of 4,027 patients with advanced schistosomiasis in China tracked mortality over six years. Roughly a quarter to a third of patients died during follow-up.

Within that cohort, liver-related markers strongly predicted death. People with ascites (fluid buildup in the abdomen) five or more times were about 50 to 75% more likely to die than those with fewer episodes. Elevated direct bilirubin doubled the risk of death, and elevated AST (a liver enzyme released when liver cells are damaged) increased it by roughly 45 to 65%. These associations held after adjusting for age, sex, nutritional status, heart and digestive comorbidities, and hepatitis B co-infection.

What this means for you: a positive result on this test is not only about the parasite in your gut today. Left untreated, intestinal schistosomiasis can progress over decades toward the kind of advanced liver disease that carries substantial mortality.

Bladder and Kidney Disease

S. haematobium lives in the veins around the bladder, and its eggs lodge in the bladder wall. A systematic review of human studies found that chronic infection drives inflammation, impairs the bladder's protective lining, alters expression of cancer-related genes including p53 and Bcl-2, and is associated with increased risk of bladder cancer. Studies in long-term immigrants living in Spain found frequent severe complications including renal failure and cirrhosis, often diagnosed only after years of silent damage. Because this species is primarily detected in urine, a negative stool test does not rule out S. haematobium infection.

Urinary schistosomiasis classically presents with blood in the urine (hematuria) and protein in the urine, but these signs can be absent or intermittent. A systematic review and meta-analysis confirmed hematuria and proteinuria as key markers but noted neither alone is reliable for diagnosis.

Nutrition, Growth, and Cognition

In children infected with S. haematobium, research has documented altered energy and purine metabolism that shifts with infection intensity and normalizes after treatment. These metabolic disturbances are linked to poorer growth, reduced physical performance, and worse cognitive function. In a cohort of 353 children in western Kenya, plasma levels of an immune marker called sTREM rose with egg density, reflecting the inflammatory load that infection imposes.

Who Should Test

Schistosomiasis is silent far more often than it is dramatic. In a study of 107 asymptomatic Eritrean refugees, 35% had active S. mansoni infection detectable by combined blood and urine testing. Among migrant children and adolescents in Spain, 10.8% tested positive and about half were asymptomatic. Among at-risk children in the Paris region, prevalence was 24.3%, with some asymptomatic children already showing organ changes on ultrasound.

Economic modeling in sub-Saharan African migrants found that both universal serologic screening and presumptive praziquantel treatment (the standard anti-parasitic drug for schistosomiasis) were cost-saving and prevented more organ damage than waiting for symptoms over a 28-year horizon. A digital decision-support tool that prompted targeted screening in migrant patients roughly doubled the number of new schistosomiasis diagnoses versus routine care.

What the Egg Test Can and Cannot Tell You

This stool-based assay looks directly for Schistosoma eggs. A positive result is highly specific for active infection. A negative result is less reassuring. Egg detection by microscopy has poor sensitivity in low-intensity or early infections, sometimes missing 50% or more of true cases. In a non-endemic Canadian setting, stool-based approaches missed many infections that serum PCR (a DNA-based test) caught with very high specificity.

For a single stool sample in a person with a low worm burden, a negative result does not fully rule out infection. That is why specialists typically combine multiple testing methods.

How the Main Schistosoma Tests Compare

What this means for you: a negative egg result is most meaningful when paired with a negative antibody or antigen test. If you have any freshwater exposure in an endemic area and a negative stool test, do not assume you are clear without follow-up serology or antigen testing.

Reference Ranges

Standardized numeric thresholds for this specific egg-based stool assay are not established in the way they are for blood chemistry tests. The result is categorical: eggs detected or not detected. For research and epidemiologic studies, the World Health Organization has historically used egg counts per gram of stool to classify light, moderate, and heavy infections, but these categories are not universally applied to individual clinical decisions outside endemic-area programs.

Compare your results within the same lab over time for the most meaningful trend, and interpret any negative result in light of your personal exposure history.

Tracking Your Trend

A single negative stool test does not close the case if you have any real exposure risk. Sensitivity improves when you submit multiple samples collected on different days, because egg shedding is intermittent. If your first test is negative and you have known freshwater exposure in an endemic area, submitting additional samples and pairing the test with serology or antigen testing is the standard approach.

After treatment with praziquantel, retest to confirm the infection has cleared. Antibody tests can stay positive for years after cure and are not useful for confirming treatment success, but egg counts should fall to zero and antigen tests should turn negative. A reasonable cadence: baseline test on suspicion, repeat stool at 4 to 6 weeks if the first is negative but exposure is high, and post-treatment confirmation at 4 to 12 weeks after praziquantel.

What to Do If Results Are Abnormal

A positive result means active infection that should be treated. The primary treatment is praziquantel, which has been studied in multiple randomized trials. Beyond treatment itself, a positive Schistosoma result should trigger a workup for organ involvement. This commonly includes a liver function panel to screen for hepatic fibrosis, a urinalysis to check for blood and protein, abdominal ultrasound to evaluate the liver, spleen, and bladder wall, and consultation with an infectious disease or tropical medicine specialist.

If you were infected with S. haematobium and have had the infection for years, you should have your bladder evaluated, because chronic urogenital schistosomiasis is a known risk factor for bladder cancer. If you have had chronic intestinal infection, hepatic imaging and liver enzyme monitoring are appropriate.

When Results Can Be Misleading

Several factors can produce a false-negative result on a single stool sample:

• Low worm burden: in light or early infections, egg shedding is sparse and easily missed on a single smear. Multiple samples improve detection.
• Timing after exposure: Schistosoma worms need roughly 6 to 8 weeks after skin penetration to mature and begin producing eggs. Testing too soon after exposure will miss early infection.
• Intermittent shedding: eggs are not released steadily, so one day's sample can be negative while the next is positive.
• Sample handling: delay between collection and lab processing, or improper preservation, can reduce egg detection.
• Wrong specimen for the species: S. haematobium eggs are shed mainly in urine, so a stool test can miss urinary schistosomiasis entirely.

None of these change whether you are infected. They change only whether this particular sample caught the evidence.

Who Benefits Most From This Test

This test is most valuable for people who have had freshwater contact in endemic regions: travelers to sub-Saharan Africa, South America, the Middle East, or Southeast Asia who swam, waded, or bathed in lakes or rivers; migrants and refugees from these areas; and anyone with unexplained hematuria, abdominal pain, or liver findings after relevant exposure. It is also valuable for asymptomatic people from endemic regions, where silent infection prevalence can exceed 20%.